RPL8 activates the SREBP1 pathway through mTORC1 in YMECs. A-B, the expression of SREBP1, mTOR and RPL8 in YMECs treated with RPL8 overexpression or RPL8 overexpression/mTOR silencing. C-E, the nuclear localization (C-D) and cytoplasmic localization (C and E) of SREBP1 in cells treated with RPL8 overexpression or RPL8 overexpression/mTOR silencing. F-G, the expression of SREBP1, mTOR and RPL8 in YMECs treated with RPL8 silencing or RPL8 silencing/mTOR overexpression. Protein expression in the “B” group was standardized to “1” in B and G, while SREBP1 localization in the nucleus and cytoplasm of the “B” group was standardized to “1” in D and E, respectively. The experimental groups were categorized as WCL (whole cell lysate), B (non-transfected cells), EV (cells transfected with empty vector), RPL8 GO (cells transfected with RPL8 overexpression vector), NC (cells transfected with negative control siRNA), Si-RPL8 (cells transfected with RPL8 siRNA), and RPL8 GO/si-mTOR (cells co-transfected with RPL8 overexpression vector and mTOR siRNA). The bar charts display superscript letters indicating significant differences (p<0.05) between different experimental groups, while identical letters indicate no significant difference (p<0.05).